Also trades as: SAN.PA (PAR) · $vol 175M · SNYNF (OTC) · $vol 2M · SNW.DE (XETRA) · $vol 1M · SNY.TO (TSX) · $vol 0M

$41.89

+0.10 (+0.24%)

Weekly Expected Move ±3.8%

$38 $40 $42 $43 $45

NASDAQ · Healthcare · Drug Manufacturers - General · Tech Score Buy · Power 58 · $100.4B mcap · 2.16B float · 0.151% daily turnover · Short 16% of daily vol

Credit Risk of going bust: lower than 81% of companies Debt: 20.7% of company value Bonds: $378.9M held by 102 funds, 19 bp over Treasuries → details ▾

If the stock fell to about $0.67 (down 98%), Sanofi would be worth roughly what it owes.
Total debt $26.24B against a stock market value of $100.37B.
Distance to default 10.01 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.97B (short-term plus half of long-term), stock volatility 23.1%; Altman Z'' 1.66. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Revenue Segmentation

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$46.7B +5.5% ▲

5Y CAGR: +4.6%

Gross Profit

$33.8B +8.7% ▲

5Y CAGR: +6.0%

Operating Income

$6.3B -12.5% ▼

5Y CAGR: -14.8%

Net Income

$7.8B +40.5% ▲

5Y CAGR: -8.7%

EPS (Diluted)

$2.03 -7.7% ▼

5Y CAGR: -16.2%

EBITDA

$12.7B +14.9% ▲

5Y CAGR: -6.6%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$39.2B	$40.6B	$41.6B	$44.3B	$46.7B
YoY Growth	+4.8%	+3.5%	+2.6%	+6.4%	+5.5%
Cost of Revenue	$12.3B	$11.9B	$12.6B	$13.2B	$12.9B
Gross Profit	$26.9B	$28.7B	$29.0B	$31.1B	$33.8B
Gross Margin	68.7%	70.7%	69.7%	70.2%	72.3%
R&D Expenses	$5.7B	$6.5B	$6.5B	$7.4B	$7.8B
SG&A Expenses	$9.6B	$8.7B	$8.9B	$9.2B	$9.5B
Operating Expenses	$18.8B	$18.5B	$22.0B	$23.8B	$27.4B
Operating Income	$8.1B	$10.2B	$7.0B	$7.3B	$6.3B
Operating Margin	20.7%	25.1%	16.7%	16.4%	13.6%
Interest Expense	$377M	$385M	$513M	$623M	$541M
Income Before Tax	$7.8B	$10.0B	$6.1B	$6.8B	$6.0B
Tax Expense	$1.6B	$1.9B	$1.0B	$1.2B	$1.0B
Net Income	$6.2B	$8.4B	$5.4B	$5.6B	$7.8B
Net Margin	15.9%	20.6%	13.0%	12.6%	16.7%
EPS (Diluted)	$2.49	$3.18	$2.15	$2.19	$2.03
EBITDA	$11.5B	$13.5B	$11.4B	$11.0B	$12.7B
Shares Outstanding	2.50B	2.50B	2.51B	2.50B	2.44B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$14.2B	$7.6B	$10.6B	$10.7B	$13.2B	$12.2B	$11.2B	$12.3B
Cost of Revenue	$4.1B	$2.3B	$2.9B	$3.0B	$3.4B	$3.6B	$3.1B	$3.0B
Gross Profit	$10.1B	$5.4B	$7.7B	$7.7B	$9.8B	$8.6B	$8.1B	$9.3B
Gross Margin	71.1%	70.2%	72.8%	72.1%	74.1%	70.3%	72.1%	75.5%
R&D Expenses	$1.9B	$2.1B	$1.8B	$1.9B	$1.8B	$2.3B	$1.7B	$2.2B
SG&A Expenses	$2.7B	$1.2B	$2.2B	$2.6B	$2.3B	$2.4B	$2.5B	$2.6B
Operating Expenses	$6.4B	$4.8B	$5.4B	$6.3B	$6.1B	$9.6B	$5.8B	$6.9B
Operating Income	$3.6B	$573M	$2.3B	$1.5B	$3.6B	-$1.0B	$2.3B	$2.4B
Operating Margin	25.7%	7.5%	21.5%	13.7%	27.5%	-8.5%	20.2%	19.4%
Interest Expense	$265M	$302M	$213M	$201M	$227M	-$101M	$178M	$287M
Income Before Tax	$3.6B	$451M	$2.2B	$1.5B	$3.5B	-$1.2B	$2.0B	$828M
Tax Expense	$737M	$4M	$481M	$230M	$680M	-$348M	$420M	$451M
Net Income	$2.8B	$499M	$1.9B	$3.9B	$2.8B	-$801M	$1.6B	$343M
Net Margin	19.9%	6.5%	17.7%	36.7%	21.3%	-6.6%	14.4%	2.8%
EPS (Diluted)	$1.13	$0.35	$0.76	$1.60	$1.14	$-1.46	$0.67	$0.14
EBITDA	$4.2B	$563M	$2.8B	$1.9B	$4.2B	$3.8B	$2.7B	$4.0B
Shares Outstanding	2.51B	2.51B	2.47B	2.47B	2.47B	2.44B	2.41B	2.39B

SNY NASDAQ